What happened with CVS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
CVS Health helps employers and health insurers manage prescription coverage through CVS Caremark. It processes prescription claims, negotiates drug prices and manufacturer rebates, and arranges access through pharmacy networks and its own specialty and mail-order pharmacies. This business earns mainly from selling and managing medicines, rather than administration fees alone. CVS Pharmacy also dispenses prescriptions, with most pharmacy revenue paid by insurers, pharmacy benefit managers and other third-party payors. Prescription medicines carry most of the pharmacy businesses’ revenue; store merchandise plays a smaller role.
Aetna provides the other major revenue source: health insurance premiums. Employers, individuals and government programs pay it for coverage. When Aetna bears the insurance risk, it pays members’ covered care costs; when an employer retains that risk, it earns fees for administering the plan. Government coverage, including Medicare and Medicaid, supplies most of Aetna’s premium revenue.
The federal government is a major customer, chiefly through Medicare contracts with the Centers for Medicare & Medicaid Services (CMS). Insurance earnings depend on care costs staying within payments set in advance, while regulators can limit premium increases. The pharmacy businesses depend on drug supply and negotiated purchasing and reimbursement terms with manufacturers, pharmacies and payors.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
CVS’s results also depend on retail prescription volumes and reimbursement, making Walgreens an important competitor to watch even though it is absent from this list.
UnitedHealth competes with CVS for health coverage, pharmacy-benefit contracts through Optum Rx, and care that takes responsibility for patients’ costs through Optum Health. Optum Health’s results from accepting monthly payments to cover care costs offer a comparison for CVS’s Oak Street Health business serving Medicare-eligible patients.
Cigna competes with CVS for contracts to manage clients’ prescription benefits through Express Scripts versus Caremark, and for health coverage through Cigna Healthcare versus Aetna. Watch the rebates Express Scripts passes to clients and the guarantees it must meet: CVS also faces pressure to share more manufacturer rebates while honoring minimum pricing guarantees.
Humana competes with CVS’s Aetna for Medicare members paying for private coverage, while CenterWell competes with CVS’s care and pharmacy operations by providing primary care, home health and pharmacy services. Humana’s Medicare insurance results and CenterWell’s operating results provide separate comparisons for CVS’s insurance and care businesses.
Elevance Health both competes with CVS’s Aetna for health-benefit premiums and employer administration fees and pays CVS Caremark to perform core pharmacy services for CarelonRx. Watch that service agreement: its current term runs through December 31, 2027, and Elevance can elect a three-year extension on the same terms if either party terminates or does not renew.
McKesson supplies the medicines CVS dispenses, making CVS a major customer responsible for approximately 24% of McKesson’s fiscal 2026 revenue. Their distribution partnership runs through June 2027, so news about its renewal matters directly to CVS’s drug supply.
Cardinal Health, which sells medicines to pharmacies and other healthcare providers, shares generic-drug purchasing with CVS through their equally owned Red Oak Sourcing venture; Red Oak negotiates supply contracts but holds no inventory. Cardinal’s generic-drug program results offer a window on shared purchasing conditions, though they also reflect its own customer volumes, pricing and sourcing costs.
Centene competes with CVS’s Aetna for government-funded Medicaid coverage, Medicare Advantage members and Medicare Part D prescription coverage. Medicaid supplied 57% of Centene’s total external revenue in 2025, making that business a useful comparison for CVS’s exposure to state funding and covered medical costs.
Molina competes with CVS’s Aetna for state Medicaid contracts and also sells Medicare coverage, collecting premiums to arrange and pay for members’ care while taking the cost risk. Medicaid generated 75% of Molina’s consolidated premium revenue in 2025, so its Medicaid results are a focused comparison for CVS’s balance between state payments and beneficiaries’ care costs.
Alignment Healthcare competes with CVS’s Aetna for Medicare Advantage members; both receive fixed payments from CMS and bear members’ medical-cost risk. Watch Alignment’s care costs against those payments as a comparison for CVS, which expects medical utilization to remain elevated in 2026.
Elevance Health, Inc. earningsELV
Elevance Health’s report will show whether its Caremark service relationship holds while it competes with Aetna for health-plan business.
Watch Elevance’s CarelonRx pharmacy-benefit services and any change in its relationship with Caremark. Elevance pays Caremark for core pharmacy services under a term running through December 31, 2027, with a three-year extension option in specified circumstances. A steady relationship would show Caremark retaining this client business; strain or change would put both that service revenue and the unusual overlap with Aetna’s competition in focus.
Molina Healthcare, Inc. earningsMOH
Molina Healthcare’s report will show whether Medicaid premiums from states keep pace with members’ care costs, a comparison for CVS’s Aetna Medicaid business.
Read Molina’s Medicaid premium revenue alongside care costs and the resulting business performance. Premiums covering costs with improving results would suggest state payments are keeping up with members’ care; costs outpacing premiums and pressuring results would signal that state Medicaid rates may be inadequate, a question for Aetna’s own ability to cover care costs with state payments.
Fed Interest Rate Decision
CVS Health’s insurer investments earn interest and support policy liabilities, so Federal Reserve rate decisions can change investment income and portfolio values, while also affecting what CVS pays to borrow.
Expected4.0%Last release4.0%
If it comes in above expectations
If rates rise more than expected, reinvested assets may earn more over time, but existing bond values may fall and new borrowing may cost more, affecting CVS Health’s investment results and financing costs.
If it comes in below expectations
If rates fall more than expected, CVS Health may earn less as investments are reinvested, while existing bond values may rise and new borrowing may cost less, changing investment results and financing costs.
CVS HEALTH CORPORATION earningsThis company
CVS’s report will show whether Aetna’s premiums cover members’ care costs and whether Caremark and its pharmacies turn drug-business growth into profit.
Start with Aetna’s medical benefit ratio—the share of premium revenue spent on care—and distinguish current medical costs from favorable adjustments to prior-year claims. Then compare adjusted operating income in Health Services and Pharmacy & Consumer Wellness with drug-business revenue growth. A lower ratio alongside resilient drug-business profit would show improvement in both insurance and pharmacy services; a rising ratio or revenue growth that fails to lift profit would show care costs or drug-pricing pressure still eroding earnings.
McKesson Corporation earningsMCK
McKesson’s report will show whether its distribution partnership with CVS is on track for renewal, a relationship tied to drug supply for CVS pharmacies.
Watch McKesson’s comments on the distribution partnership and its renewal. The arrangement runs through June 2027, and McKesson says CVS accounts for about 24% of its fiscal 2026 revenue. A clear renewal would support continuity of an important supply channel; uncertainty would raise the risk of changed supply arrangements, though McKesson’s report alone would not establish that CVS faces a drug shortage.
